Urolithin D

Urolithin D (3,4,8,9-Tetrahydroxy urolithin) is a colonic metabolite of Ellagitannins and a competitive, reversible, and selective antagonist of the EphA receptor. Urolithin D inhibits EphA2-ephrin-A1 binding with an IC50 of 0.9 μM. Urolithin D is also a potent antioxidant that scavenges free radicals and repairs oxidized DNA damage. Additionally, Urolithin D suppresses triglyceride accumulation and promotes fatty acid oxidation by activating the AMPK signaling pathway. Urolithin D can be used for research on tumors, metabolic, and inflammatory diseases[1][2][3].

Product Specifications

CAS Number

[131086-98-1]

Product Name Alternative

3,4,8,9-Tetrahydroxy urolithin

UNSPSC

12352005

Hazard Statement

H315, H319

Target

AMPK; Ephrin Receptor; PPAR

Type

Natural Products

Related Pathways

Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Vitamin D Related/Nuclear Receptor

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/urolithin-d.html

Purity

99.72

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C1C2=CC(O)=C(O)C=C2C3=CC=C(O)C(O)=C3O1

Molecular Formula

C13H8O6

Molecular Weight

260.20

Precautions

H315, H319

References & Citations

[1]Giorgio C, et al. The ellagitannin colonic metabolite urolithin D selectively inhibits EphA2 phosphorylation in prostate cancer cells. Mol Nutr Food Res. 2015 Nov;59 (11) :2155-67. |[2]Kang I, et al. Urolithin A, C, and D, but not iso-urolithin A and urolithin B, attenuate triglyceride accumulation in human cultures of adipocytes and hepatocytes. Mol Nutr Food Res. 2016 May;60 (5) :1129-38.|[3]Milanović Ž. Urolithin D: A promising metabolite of ellagitannin in combatting oxidative stress. Chem Biol Interact. 2025 Apr 25;411:111444.